Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the Netherlands / NCT07556263
Recruiting Observational

Mobility and Activity of Daily Living Outcomes After a Hip Fracture.

NCT07556263 · tracked via the Priya Life Science Netherlands tracker
Phase
Observational
Started
2016-01-01
Last updated
2026-06-04

Condition(s) studied

Hip Fractures (ICD-10 72.01-72.2)

Study summary

Hip fractures in especially older adults cause severe clinical and functional impacts. Despite improved surgical care, one year mortality remains 14-30%, and fewer than half of the survivors regain their pre-fracture functional status. After a hip fracture, patients are primarily concerned with what they will be able to do in daily life. Wihout accurate predictions of mobility and Activities of Daily Life (ADL) independence, it is difficult to set realistic expectations and make appropriate decisions regarding treatment and rehabilitation. While there have been advancements in developing predictive models for mortality following hip fractures, there is a notable gap in models focused on predicting functional recovery. This study aims to develop and validate a machine learning-based model that can predict mobility and ADL independence three months after obtaining a hip fracture.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient has been treated for a hip fracture in OLVG hospital betweek 01-01-2016 and 31-12-2025 * Patient was 18 years or older at the time of the injury Exclusion Criteria: * The patient does not grant permission for the use of their data for studies

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
OLVG hospital Amsterdam Netherlands Recruiting

More JointResearch trials in the Netherlands

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07556263 on ClinicalTrials.gov ↗ ← All trials in the Netherlands